Form 8-K - Current report:
SEC Accession No. 0001493152-23-012602
Filing Date
2023-04-17
Accepted
2023-04-17 17:25:50
Documents
13
Period of Report
2023-04-11
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53691
  Complete submission text file 0001493152-23-012602.txt   286516

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bfri-20230411.xsd EX-101.SCH 4288
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bfri-20230411_def.xml EX-101.DEF 27600
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bfri-20230411_lab.xml EX-101.LAB 38253
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bfri-20230411_pre.xml EX-101.PRE 26217
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6875
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 23824849
SIC: 2834 Pharmaceutical Preparations